Neoadjuvant Intralesional Daromun Improves Relapse Free Survival in Stage III Melanoma
The phase 3 PIVOTAL study has shown that neoadjuvant intralesional daromun can benefit patients with pretreated stage III melanoma.
Read MoreJun 10, 2024
The phase 3 PIVOTAL study has shown that neoadjuvant intralesional daromun can benefit patients with pretreated stage III melanoma.
Read MoreJun 10, 2024
A curated ebook on chronic obstructive pulmonary disease (COPD featuring recent studies, findings, and opinions from thought leaders.
Read MoreJun 7, 2024
A study finds 1 year of avelumab treatment improves distant disease free and overall survival rates in patients with early triple-negative breast cancer.
Read MoreJun 7, 2024
An analysis of the benefits of nivolumab/ipilimumab in MSI-H/dMMR metastatic colorectal cancer on progression free survival rate.
Read MoreJun 7, 2024
Virtual or in person palliative care has shown significant results for patients with non-small cell lung cancer that is incurable.
Read MoreJun 7, 2024
Patients with resectable oesophageal cancer have better results with perioperative chemotherapy and surgery than neoadjuvant chemoradiation and surgery.
Read MoreJun 7, 2024
Metformin, has been found to not benefit patients with low risk prostate cancer.
Read MoreJun 6, 2024
Batiraxcept and paclitaxel as a combination therapy has shown significant results in improving progression free survival and overall rates.
Read MoreJun 6, 2024
A curated ebook on Crohn’s and colitis featuring recent studies, findings, and opinions from thought leaders.
Read MoreJun 6, 2024
Patients with macroscopic stage 3 melanoma have seen improvements with neoadjuvant ipilimumab/nivolumab intake.
Read MoreJun 6, 2024
A phase 3 trial has found that there is no survival benefit for tumor debulking in addition to palliative combination chemotherapy.
Read MoreJun 6, 2024
Abemaciclib in combination with fulvestrant can benefit progression free survival rates in patients with HR+/HER2-negative breast cancer.
Read MoreJun 6, 2024
An analysis has found that lorlatinib did not reach median progression free survival rates.
Read MoreMay 29, 2024
Recent studies highlight the growing interest surrounding the use of IV iron for patients with HFrEF and iron deficiency.
Read MoreMay 29, 2024
A curated ebook on tardive dyskinesia featuring recent studies, findings, and opinions from thought leaders.
Read MoreMay 28, 2024
Researchers at the 2024 ASCO Annual Meeting found racial and ethnic disparities in palliative care use among patients with advanced hepatocellular carcinoma.
Read MoreMay 28, 2024
Fixed duration ibrutinib plus venetoclax benefited survival outcomes in patients with high-risk CLL/SLL over more than 5 years of follow-up.
Read MoreMay 28, 2024
Investigators examined the changes in mortality rates due to COVID-19, influenza, and pneumonia in patients with MM.
Read More